Neurotune Overview

  • Founded
  • 2005

Founded
  • Status
  • Private

  • Employees
  • 5

Employees
  • Latest Deal Type
  • Angel

  • Investors
  • 4

Neurotune General Information

Description

Operator of a drug discovery and development biotech company intended to work on neuropathic pain. The company provides C-terminal fragments of agrin and enzyme-linked immunosorbent assay, and diagnostic assays for the detection of the C-terminal fragment of an agrin biomarker for renal disease detection, enabling patients to have access to offer medications for neuromuscular diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Primary Office
  • Wagistrasse 27 a
  • 8952 Schlieren
  • Switzerland
+41 044 000 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurotune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Angel (individual) 29-Jul-2008 00.00 Completed Stealth
4. Seed Round 13-Apr-2007 00.000 00.00 0000 Completed Stealth
3. Seed Round 17-Jul-2006 00.000 00.000 00.000 Completed Stealth
2. Seed Round 23-Dec-2005 $1.07M $1.07M 00.000 Completed Startup
1. Angel (individual) Completed Startup
To view Neurotune’s complete valuation and funding history, request access »

Neurotune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000,000 00.00 00.00 00 00.00 00.000
Ordinary 0,000,000 00.00 00.00 00 00.00 00.000
To view Neurotune’s complete cap table history, request access »

Neurotune Patents

Neurotune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-2631657-A1 Immunoassay for the detection of the 22kda c-terminal fragment (caf) of agrin Inactive 25-Feb-2012 000000000 0
EP-2817634-A1 Method for the determination of renal function Inactive 25-Feb-2012 000000000
US-20150031057-A1 Method for the determination of renal function Inactive 25-Feb-2012 00000000000
EP-2484695-A1 A method for the production of hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human c44-fragment of agrin Inactive 04-Feb-2011 000000000 0
EP-2670777-A1 A method for the production of hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human c44-fragment of agrin Inactive 04-Feb-2011 C07K16/18
To view Neurotune’s complete patent history, request access »

Neurotune Executive Team (4)

Name Title Board Seat Contact Info
Bruno Oesch Ph.D Co-Founder & Executive Chairman
Armin Mäder Ph.D Co-Founder & Board Member
You’re viewing 2 of 4 executive team members. Get the full list »

Neurotune Board Members (1)

Name Representing Role Since
Armin Mäder Ph.D Self Co-Founder & Board Member 000 0000
To view Neurotune’s complete board members history, request access »

Neurotune Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurotune Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Prionics Corporation Minority 000 0000 000000 0
Private Equity Invest PE/Buyout Minority 000 0000 000000 0
Zürcher Kantonalbank Corporation Minority 000 0000 000000 0
BioBac Angel Group Minority 000 0000 000000 0
To view Neurotune’s complete investors history, request access »